INCY: Buying Interest Emerges as Uptrend HoldsIncyte CorporationBATS:INCYfinvestnomicsINCY is seeing renewed buying interest after retracing toward its 20-day moving average, potentially providing an opportunity for investors to participate in the stock’s ongoing uptrend. The stock continues to make higher highs and higher lows while trading above both the 20-day and 50-day moving averages, signaling that the broader bullish trend remains intact. Incyte Corp. is a $26 billion market-cap biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company primarily operates across hematology and oncology, inflammation, and autoimmunity therapeutic areas. INCY is currently classified as a no-moat company and has delivered strong recent fundamental performance. Revenue and EPS have grown year over year in each of the last three quarters, with the most recent growth rates at 38% and 40%, respectively. The company has an operating margin of 42% and a net margin of 35%, while ROE and ROIC stand at 31% and 30%, respectively. Its current ratio of 4.6x and extremely low debt-to-equity ratio of 0.01x reflect a strong liquidity position and minimal leverage. Looking ahead, revenue is forecast to continue growing over the next three quarters, with 18% growth expected in the next quarter. EPS, however, is expected to decline in the next quarter, remain relatively flat in the second quarter, and then accelerate to approximately 23% growth in the third quarter. The average analyst price target is approximately $128.91, representing about 1% upside potential. While the limited analyst upside suggests that valuation may already reflect much of the expected growth, the stock’s higher-highs and higher-lows structure makes INCY an interesting technical setup to monitor.